

(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407	Serial Number: 10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

- NOTE: If no indication is made in the column marked "COPY NOTE," the required legible copy of the corresponding item is submitted herewith; otherwise, a copy is not required and/or not submitted, for the following reason(s) [corresponding reason number is listed in "COPY NOTE" column]
- (1) This item is cumulative, per Rule 98(c)
 - (2) A copy of this item was previously cited by or submitted to the U.S. Patent and Trademark Office in:
 USSN _____, filed _____, or
 USSN _____, filed _____;
 Relied on under 35 U.S.C. Section 120, per Rule 98(d)
 - (3) Both reasons (1) and (2) apply
 - (4) No legible complete copy is possessed, in custody of controlled, or readily available
 - (5) Per the U.S. Patent and Trademark Office's waiver of Rule 98(a)(2)(i), the item is a U.S. patent or patent application publication, and the present application was filed after June 30, 2003.

U.S. PATENT DOCUMENTS				
EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER	ISSUE DATE	COPY NOTE

U.S. PATENT APPLICATION PUBLICATIONS				
EXAMINER INITIALS	APPLICANT'S NAME	PUBLICATION NUMBER	PUBLICATION DATE	COPY NOTE

FOREIGN PATENT DOCUMENTS												
EXAMINER INITIALS		COUNTRY	DOCUMENT NUMBER					PUBLICATION DATE	TRANSLATION			COPY NOTE
									YES	NO	N/A	

*"NO" means that no copy of an English language translation is within the possession, custody, or control of, or is readily available to any individual designated in Rule 56(c).

EXAMINER INITIALS	OTHER DOCUMENTS		COPY NOTE
	Specify author (if any), Title, Pertinent Pages, Date & Place of Publication		
mt	1	Article - <i>A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer</i> , Zhang et al., Clinical Cancer Research, Vol. 8, April 2002, pp. 1196-1205	
mt	2	Article - <i>Deposition of laminin 5 in epidermal wounds regulates integrin signaling and adhesion</i> , Nguyen et al., Current Opinion in Cell Biology, Vol. 12, 2000, pp. 554-562	

Mahn Haddad

1/9/06

(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: CXU-407		Serial Number: 10/817,423
	Applicant: Scott, et al.		
	Filing Date: April 2, 2004	Group Art Unit: 16464	
	Confirmation No: 1563		

MH	3	Article - Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A, Langenheim et al., Breast Cancer Research and Treatment, Vol. 90, 2005, pp. 281-293		
	4	Article - From genes to protein structure and function: novel applications of computational approaches in the genomic era, Skolnick et al., Tibtech, Vol. 18, January 2000, pp. 34-39		
MH	5	Article - Globular domains 4/5 of the laminin α3 chain mediate deposition of precursor laminin 5, Sigle et al., Journal of Cell Science, Vol. 117, No. 19, May 12, 2004, pp. 4481-4494		
MH	6	Article - Homozygous α6 integrin mutation in junctional epidermolysis bullosa with congenital duodenal atresia, Pulkkinen et al., Human Molecular Genetics, Vol. 6, No. 5, 1997, pp. 669-674		
	7	Article - IgG Autoantibodies in Patients with Anti-Epithelial Cicatricial Pemphigoid Recognize the G Domain of the Laminin 5 α Subunit, Lazarova et al., Clinical Immunology, Vol. 101, No. 1, October 2001, pp. 100-105		
	8	Article - Immunosuppressive therapy, Barry D. Kahan, Immunology, Vol. 4, 1992, pp. 559-560		
	9	Article - Ligand binding to proteins: The binding landscape model, Miller et al., Protein Science, Vol. 6, 1997, pp. 2166-2179		
	10	Article - Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, Burgess et al., The Journal of Cell Biology, Vol. 111, 1990, pp. 2429-2438		
MH	11	Article - Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer, Beck et al., Cancer Research, Vol. 63, July 1, 2003, pp. 3598-3604		
MH	12	Article - Structure and assembly of hemidesmosomes, Jones et al., BioEssays, Vol. 20, 1998, pp. 488-494		
MH	13	Article - Structure and Function of Hemidesmosomes: More Than Simple Adhesion Complexes, Borradori et al., The Journal of Investigative Dermatology, Vol. 112, No. 4, April 1999, pp. 411-418		

Maher Haddad 1/9/06

(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number:	Serial Number:
	CXU-407	10/817,423
	Applicant: Scott, et al.	
	Filing Date: April 2, 2004 Confirmation No: 1563	Group Art Unit: 1646

	14	Article - Structure-Based Strategies for Drug Design and Discovery, Irwin D. Kuntz, Science, Vol. 257, 21 August 1992, pp. 1078-1082		
mt	15	Article - Targeted Disruption of the LAMA3 Gene in Mice Reveals Abnormalities in Survival and Late Stage Differentiation of Epithelial Cells, Ryan et al., The Journal of Cell Biology, Vol. 145, No. 6, June 14, 1999, pp. 1309-1323		
	16	Article - The Babel of Bioinformatics, Teresa K. Attwood, Science, Vol. 290, 20 October 2000, pp. 471-473		
mt	17	Article - The Functions of Laminins: Lessons from In Vivo Studies, Ryan et al., Matrix Biology, Vol. 15, 1996, pp. 369-381		
EXAMINER		Maher Haddad	DATE CONSIDERED 1/9/06	
Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.				